探索神经退行性疾病患者的非药理学辅助疗法
Maria Marchiș1,2, Magdalena Iorga1,2
1Faculty of Psychology and Education Sciences, "Alexandru Ioan Cuza" University, 700554 Iasi, Romania.
Medicina (Kaunas, Lithuania)
|July 30, 2025
概括
像神经调节这样的替代疗法对神经退行性疾病有希望,改善情绪和认知功能. 这些非侵入性方法为患者护理和护理人员支持提供了新的途径.
科学领域:
- 神经科学是一个神经科学.
- 康复医学 康复医学 康复医学
- 心理学 心理学 心理学
背景情况:
- 神经退行性疾病在患者管理中存在重大挑战.
- 替代疗法正在成为综合护理计划的关键组成部分.
- 非侵入性神经调节技术因其潜在的益处而受到越来越多的关注.
研究的目的:
- 审查神经退行性疾病的替代疗法的有效性.
- 评估神经调节对认知和情绪功能的影响.
- 评估这些疗法在患者和护理人员管理中的作用.
主要方法:
- 在2025年2月进行了全面的文献审查.
- 搜索包括主要的学术数据库:谷歌学者,PubMed,Scopus和科学网.
- 分析了2020年至2025年间发表的20项研究,这些研究符合纳入标准.
主要成果:
- 创新的神经调节疗法在治疗神经退行性疾病方面具有很高的潜力.
- 这些非侵入性技术会对患者的情绪和认知症状产生积极影响.
- 初步发现表明,这些方法可以补充或取代传统干预措施,使护理人员受益.
结论:
- 替代疗法,包括神经调节,认知疗法,VR和心理支持,对于神经退行性疾病来说是有前途的.
- 这些方法提供了可行的选择,特别是当基于药物的治疗不适合时.
- 需要进一步的研究来建立治疗方案,并确认改善生活质量的长期疗效.
相关概念视频
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Parkinson's Disease: Treatment
381
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
381
Heart Failure VI: Adjunct Therapies
28
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
28
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
208
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
208
Parkinson's Disease: Overview
710
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
710


